Literature DB >> 1464154

A review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions.

D A Williams1, J Lokich.   

Abstract

It is important that the stability of reconstituted parenteral antineoplastic agents be established, particularly in the context of ambulatory infusion systems for delivery. The stability of selected agents within each of the five classes of compounds (antimetabolites, alkylating agents, antibiotics, alkaloids and glycosides, and metals) is reviewed from the literature together with additional data from studies carried out using high-performance liquid chromatographic (HPLC) technology in clinically applicable volumes and concentrations for ambulatory infusion. The stability of reconstituted drugs varies from a few minutes (mecloethamine) to many months (FU). Compatibility data on two- and three-drug admixtures of cytotoxic agents are reported for a number of common multidrug regimens. Tabular presentation of the drug-drug compatibilities and incompatibilities is included along with a discussion of the mechanisms for drug-drug interaction. The use of a broad spectrum of compatible cytotoxic drugs is possible, including fluoropyrimidine-, anthracycline-, and platinum-based combinations, providing the capability of carrying out multidrug infusions for 4-7 days in an ambulatory delivery system.

Entities:  

Mesh:

Year:  1992        PMID: 1464154     DOI: 10.1007/bf00685544

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Etoposide admixed with cisplatin. Phase I clinical investigation of 72-hour infusion.

Authors:  J Lokich; N Anderson; M Bern; S Wallach; C Moore; D Williams
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

Review 2.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Stability of anthracycline antitumour agents in infusion fluids.

Authors:  J H Beijnen; H Rosing; P A de Vries; W J Underberg
Journal:  J Parenter Sci Technol       Date:  1985 Nov-Dec

4.  Chemical stability of cyclophosphamide in parenteral solutions.

Authors:  D Brooke; R J Bequette; R E Davis
Journal:  Am J Hosp Pharm       Date:  1973-02

5.  Photolytic degradation of adriamycin.

Authors:  N Tavoloni; A M Guarino; P D Berk
Journal:  J Pharm Pharmacol       Date:  1980-12       Impact factor: 3.765

6.  The stability of carboplatin in ambulatory continuous infusion regimes.

Authors:  G J Sewell; C M Riley; C G Rowland
Journal:  J Clin Pharm Ther       Date:  1987-12       Impact factor: 2.512

7.  Stability of anthracycline antitumor agents in four infusion fluids.

Authors:  G K Poochikian; J C Cradock; K P Flora
Journal:  Am J Hosp Pharm       Date:  1981-04

8.  Combined 5-fluorouracil and floxuridine administered as a 14-day infusion. A phase I study.

Authors:  N Anderson; J Lokich; M Bern; S Wallach; C Moore; D Williams; V Umprayn
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

9.  Stability of cancer chemotherapeutic agents in a totally implanted drug delivery system.

Authors:  J H Keller; W D Ensminger
Journal:  Am J Hosp Pharm       Date:  1982-08

10.  Combined floxuridine and cisplatin in a fourteen day infusion. Phase I study.

Authors:  J Lokich; N Anderson; M Bern; S Wallach; C Moore; D Williams; V Umprain
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

View more
  2 in total

1.  Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244).

Authors:  J D Jonkman-de Vries; M J de Graaff-Teulen; R E Henrar; J J Kettenes-van den Bosch; A Bult; J H Beijnen
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

2.  Pharmaceutical Development of 5-Fluorouracil-Eluting Stents for the Potential Treatment of Gastrointestinal Cancers and Related Obstructions.

Authors:  Mohammad Arafat; Yunmei Song; Kyle Brewer; Paris Fouladian; Ankit Parikh; Hugo Albrecht; Anton Blencowe; Sanjay Garg
Journal:  Drug Des Devel Ther       Date:  2021-04-09       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.